|Day Low/High||143.22 / 144.66|
|52 Wk Low/High||109.16 / 157.00|
A weak dollar could provide a substantial tailwind for these companies.
The battle to gain control over Covid-19 is entering a crucial stage and calls for continued determination.
A look at the charts of Advanced Micro Devices and Tesla, plus a review of the 'broadening' market action from Thursday.
One of the most-hated sectors of the market is taking off, and it's not too late to get on board.
What happens when everyone hunkers down, creating their own de facto stay-in-place lockdown?
Monday's action in Johnson & Johnson is a fadeable event.
Portfolio managers are starting to see a very strong 2021 for markets and the economy regardless of electoral results.
Markets have certainly recovered nicely off of the lows of late September. Now, here in mid-October, it feels like it did that cold night back in 1980-something. The wolves are visible and noisy.
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Market participants ignore negative news and continue to pursue individual stocks into earnings season.
Given the news of the day, you'd think we would have had a violent pullback -- instead here's what we got.
Some patterns reveal themselves easily, and you can spot them ahead of the computer programs. Here are examples of them, and how to act.
Let's talk about what's happening right now to get this thing under control and what it will look like not that long from now.
Now, that we have confirmation from the Nasdaq Composite, I think we can say equity markets are indeed back in what I would consider an uptrend.
There was some significant rotational action Monday and we'll see if that continues as we move into earnings reports.
The market is reflecting a triumph of big business over small business, and here's what that means for individual stocks.
Neither candidate seems to be the enemy of the market -- at least not yet.
I see no reason to flee this name, therefore, I am not.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
The greedy are, at last, getting blown out, and the prudent being vindicated. I see three buckets of stocks that intrigue me now.
The 10-year U.S. note auction was soft. The yield of 0.704% was above the when issued of about 0.695%. The bid to cover of 2.30 was below the 12 month average of 2.47. Also, dealers were left with 27% of the auction vs. the one year average of 25%. ...
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
The equity market recovery is just as sloppy in performance as the economy itself.
If you're looking for some corrective action to gain momentum, then you will have to wait for broader selling.
Here's how we would trade the blue chip stock.
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.